Examples of using Hyperkalaemia in English and their translations into Slovenian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Official/political
-
Programming
Hyperkalaemia has been observed in isolated cases.
The main risk factors for hyperkalaemia to be considered are:.
Hyperkalaemia has been observed in isolated cases.
When injected intravenously it causes hyperkalaemia, then heart failure.
Metabolic disturbances include hyperglycaemia, metabolic acidosis and hypo- or hyperkalaemia.
There is a risk for premature delivery(< 37 week) as well as for hyperkalaemia in the newborn, which, however, normalizes spontaneously.
It is therefore recommended to monitor plasma potassium levels when using FORTEKOR PLUSin combination with a potassium sparing diuretic because of the risk of hyperkalaemia.
Tumour lysis can also result in hyperphosphataemia, hyperkalaemia and hypocalcaemia.
Medicinal products that may increase potassium levels or induce hyperkalaemia(e.g. ACE inhibitors, potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, cyclosporin or other medicinal products such as heparin sodium).
Do not use in dogs suffering from hypoadrenocorticism, hyperkalaemia or hyponatraemia.
As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics(e.g. amiloride, triamterene, or spironolactone) should be avoided(see section 4.4).
Do not use in dogs suffering from hypoadrenocorticism, hyperkalaemia or hyponatraemia.
Prolonged ACE inhibitor exposure during the second and third trimesters is known to induce human foetotoxicity(decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity(renal failure,hypotension, hyperkalaemia).
Overdose of potassium isnot as frequently encountered in clinical practice as hyperkalaemia due to acute or chronic renal disease.
In diabetic hypertensive patients with microalbuminuria andnormal renal function, hyperkalaemia(≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group.
Conversely, due to the aliskiren component of Rasilez HCT, hyperkalaemia might occur.
This syndrome may be associated with some features oftumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphaetemia, acute renal failure, elevated Lactate dehydrogenase(LDH) and may be associated with acute respiratory failure and death.
Newborns whose mothers have taken ACE inhibitors should be closely observed for hypotension,oliguria and hyperkalaemia(see also sections 4.3 and 4.4).
This syndrome may be associated with some features oftumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphaetemia, acute renal failure, elevated Lactate dehydrogenase(LDH) and may be associated with acute respiratory failure and death.
The most common side effects with Rasilez(seen in between 1 and 10 patients in 100) are dizziness, diarrhoea,arthralgia(joint pain) and hyperkalaemia(high blood potassium levels).
In diabetic hypertensive patients with chronic renal insufficiency andovert proteinuria, hyperkalaemia(≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.
Concomitant administration of spironolactone with ACE-inhibitors and other potassium-sparing drugs(as angiotensin receptor blockers, ß-blockers, calcium channels blockers… etc)may potentially lead to hyperkalaemia(see section 4.5).
Although serum potassium usually remains within normal limits, hyperkalaemia may occur in some patients treated with perindopril.
The concomitant administration of this veterinary medicinal product with other potassium-sparing treatments(such as ß-blockers, calcium channels blockers, angiotensin receptor blockers)may potentially lead to hyperkalaemia(see section 4.5).
Uncommon: blood urea nitrogen increased, creatine phosphokinase increased, haematocrit decreased,haemoglobin decreased, hyperkalaemia, leukocytes decreased, platelets decreased, serum creatinine increased, uric acid increased.
Concomitant administration of spironolactone with ACE-inhibitors and other potassium-sparing drugs(as angiotensin receptor blockers, ß-blockers, calcium channels blockers, etc)may potentially lead to hyperkalaemia(see section"Special precautions for use in animals").
In animals,lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene.
Regular monitoring should continue in dogs with reduced kidneyfunction as they may have an increased risk of hyperkalaemia(raised potassium levels in the blood) during treatment.
Caution should be exercised in patientstaking drospirenone-containing medicines with conditions that predispose them to hyperkalaemia or patients taking potassium-sparing diuretics.
Combination of Entresto with aliskiren is potentially associated with a higherfrequency of adverse events such as hypotension, hyperkalaemia and decreased renal function(including acute renal failure)(see sections 4.3 and 4.4).